The role of serotonin and neurotransmitters during craniofacial development.
Several neurotransmitters, in particular serotonin (5-HT), have demonstrated multiple functions during early development and mid-gestational craniofacial morphogenesis. Early studies indicated that 5-HT is present in the oocyte, where it appears to function as a regulator of cell cleavage. Later, it has a significant role during gastrulation, during which there are significant areas of 5-HT uptake in the primitive streak. Subsequently, in association with neurulation, 5-HT uptake is seen in the floor plate of the developing neural tube. During neural crest formation and branchial arch formation, 5-HT has been demonstrated to facilitate cell migration and stimulate cell differentiation. During morphogenesis of the craniofacial structures, 5-HT stimulates dental development and may aid in cusp formation. All of the most commonly prescribed antidepressant drugs inhibit serotonin uptake, yet they do not appear to cause major craniofacial malformations in vivo. Given the wide spectrum of effects that 5-HT has during development, it is difficult to understand why these anti-depressants are not major teratogens. Redundancy within the system may allow receptor and uptake pathways to function normally even with lower than normal levels of circulating serotonin. Serotonin-binding proteins, that are expressed in most craniofacial regions at critical times during craniofacial development, may have a buffering capacity that maintains adequate 5-HT tissue concentrations over a wide range of 5-HT serum concentrations. Dental development appears to be particularly sensitive to even small fluctuations in concentrations of 5-HT. Therefore, it may be that children of patients who have received selective serotonergic re-uptake inhibitors (such as Prozac and Zoloft) or the less selective tricyclic anti-depressant drugs (such as Elavil) would be at a higher risk for developmental dental defects such as anodontia and hypodontia. In this review, the evidence supporting a role for 5-HT during mammalian craniofacial development is discussed. A series of models is proposed that may explain how the craniofacial effects of 5-HT are mediated.
Moiseiwitsch
J R
JR
Department of Endodontics, School of Dentistry, University of North Carolina, Chapel Hill 27599-7450, USA. julian@dentistry.unc.edu
D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects; D001934:Branchial Region / Q000196:embryology; D002352:Carrier Proteins / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D002465:Cell Movement / Q000502:physiology; D005314:Embryonic and Fetal Development / Q000502:physiology; D005145:Face / Q000196:embryology*; D005147:Facial Bones / Q000196:embryology*; D005260:Female; D005775:Gastrula / Q000502:physiology; D006801:Humans; D009024:Morphogenesis / Q000502:physiology; D009432:Neural Crest / Q000502:physiology; D018377:Neurotransmitter Agents / Q000502:physiology*; D009805:Odontogenesis / Q000502:physiology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D012701:Serotonin / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D015398:Signal Transduction / Q000502:physiology; D012886:Skull / Q000196:embryology*; D013723:Teratogens; D014071:Tooth Abnormalities / Q000139:chemically induced
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D002352:Carrier Proteins; D018377:Neurotransmitter Agents; D011985:Receptors, Serotonin; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013723:Teratogens; C025366:serotonin-binding protein